Statistics
Publications
2
Citations
26
H-Index
2
Active since
2022
Affiliations
Incyte (United States)(Current)
Kai Liu is an author at Incyte (United States) specializing in immune checkpoint inhibitor therapy, pharmacy, and drug discovery.
Publications per year
2022–2022
2
2
Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors
Qinda Ye, Kai Liu, Hai‐Fen Ye et al. · ACS Medicinal Chemistry Letters · 2022 · 14 citations · Full text
1–2 of 2